Alto Neuroscience Analyst Ratings
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience Stock Crashes Amid Failed Study, Wedbush Downgrade
Wedbush Downgrades Alto Neuroscience to Neutral Following ALTO-100 Readout
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Alto Neuroscience Is Maintained at Outperform by Baird
Alto Neuroscience Analyst Ratings
Alto Neuroscience Downgraded to Neutral From Buy at Rodman & Renshaw
Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Buy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical Developments
Alto Neuroscience Analyst Ratings
Wedbush Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $29
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Analysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)
Wedbush Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $29
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $33
Alto Neuroscience, Inc. (ANRO) Gets a Buy From Jefferies
Buy Rating Affirmed for Alto Neuroscience, Inc. on Strong Clinical Trials and Strategic Precision Neuroscience Approach
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
No Data
No Data